PDF herunterladen
Thromb Haemost 1960; 4(03): 376-388
DOI: 10.1055/s-0038-1654521
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Plasma Thromboplastin Component (Christmas Factor, Factor IX) Levels in Stored Human Blood and Plasma[*]

J Dieter Geratz
1   Department of Pathology University of North Carolina Chapel Hill, North Carolina, USA
,
John B. Graham
1   Department of Pathology University of North Carolina Chapel Hill, North Carolina, USA
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
17. Juni 2018 (online)

    Lizenzen und Reprints

Summary

1. PTC activity was assayed in 26 units of human plasma prepared from whole blood stored for 3 weeks at 4° C. The plasma had been frozen and stored at — 20° C for additional periods ranging from a few days to 4 months. High PTC activity was still present in the plasma at the end of this period, the activity averaging 95% of normal.

2. The PTC activity of 19 samples of “reclaimed“ plasma stored for an additional 6 months at — 20° C decreased by an average of 23%. This decrease was statistically significant.

3. Liquid plasma kept at room temperature for 5½—7½ months contained no PTC activity.

4. Lyophilized plasma stored at room temperature for 6—8 years contained an average of 30% PTC activity. Lyophilized plasma stored at — 20° C for 4 years contained 68% PTC activity.

5. ACD and disodium hydrogen citrate anticoagulant solutions served equally well in preserving PTC activity in whole blood stored in glass tubes over a period of 3 weeks at 4° C.

6. “Reclaimed“ plasma from outdated bank blood provided effective hemostasis in two operations for the removal of 20 teeth from a severely PTC-deficient patient.

7. The high PTC activity of “reclaimed“ plasma was confirmed by the close agreement between the PTC level expected in a PTC deficient patient after transfusion of such plasma and that observed.

* Supported (in part) by research grants H-1333 and H-3140 of the National Heart Institute, Public Health Service.


 

  • References

  • (1) Aggeler P. M. Plasma Thromboplastin Component (PTC) Deficiency. Hemophilia and Hemophilioid Diseases. 111 Brinkhous K. M. Ed. University of North Carolina Press; Chapel Hill: 1957
    Google Scholar
  • (2) Aggeler P. M, White S. E, Glendening M. B, Page W. E, Leake T. B, Bates G. Plasma Thromboplastin Component (PTC) Deficiency: A New Disease Resembling Hemophilia. Proc. Soc. exp. Biol. (N. Y.) 79: 692 1952;
    CrossrefPubMedGoogle Scholar
  • (3) Brinkhous K. M. Discussion. Hemophilia and Hemophilioid Diseases. 132 Brinkhous K. M. Ed. University of North Carolina Press; Chapel Hill: 1957
    Google Scholar
  • (4) Barrow E. M, Bullock W. R, Graham J. B. A Study of the Carrier State for Plasma Thromboplastin Component (PTC, Christmas Factor) Deficiency, Utilizing a New Assay Procedure. J. Lab. clin. Med.. 1960 (in press).
    PubMedGoogle Scholar
  • (5) Biggs R, Douglas A. S, Macfarlane R. G, Dacie J. V, Pitney W. R, Merskey C, O'Brien J. R. Christmas Disease. A Condition Previously Mistaken for Hemophilia. Brit. med. J. 2: 1378 1952;
    CrossrefPubMedGoogle Scholar
  • (6) Brafield A. J, Case J. The Stability of Christmas Factor. A Guide to the Management of Christmas Disease. Lancet 271: 867 1956;
    PubMedGoogle Scholar
  • (7) Graham J. B, Barrow E. M. The Pathogenesis of Hemophilia. An Experimental Analysis of the Anticephalin Hypothesis in Hemophilic Dogs. J. exp. Med. 106: 273 1957;
    CrossrefPubMedGoogle Scholar
  • (7a) Graham J. B, Geratz J. D. Recent Experiences with Transfusion Therapy in PTC-Deficiency. Proc. VII Congr. Internat. Soc. Blood Transf., Rome, 1958. 993 S. Karger; Basel: 1959
    Google Scholar
  • (8) Grant R. T, Reeve E. B. Observations on the General Effects or Injury in Man With Special Reference to Wound Shock. Medical Research Council; Special Report Series No. 277 233 1951
    Google Scholar
  • (9) Langdell R. D, Bowersox L. W, Weaver R. A, Gibson W. S. Coagulation of Normal Canine Lymph. Fed. Proc. 18: 487 1959;
    PubMedGoogle Scholar
  • (10) Langdell R. D, Wagner R. H, Brinkhous K. M. Effect of Antihemophilic Factor on One-Stage Clotting Tests. J. Lab. clin. Med. 41: 637 1953;
    PubMedGoogle Scholar
  • (11) Myant N. B. Observations on the Metabolism of Human Gamma Globulin Labelled by Radioactive Iodine. Clin. Sci. 11: 191 1952;
    PubMedGoogle Scholar
  • (12) Nour-Eldin F, Wilkinson J. F. Changes in the Blood Clotting Defect in Christmas Disease after Plasma and Serum Transfusions. Clin. Sci. 17: 303 1958;
    PubMedGoogle Scholar
  • (13) Rodman N. F, Barrow E. M, Graham J. B. Diagnosis and Control of the Hemophilioid States with the Partial Thromboplastin Time (PTT) Test. Amer. J. clin. Path. 29: 525 1958;
    PubMedGoogle Scholar
  • (14) Rosenthal M. C, Sanders M. Plasma Thromboplastin Component Deficiency. I. Studies on its Inheritance and Therapy. Amer. J. Med. 16: 153 1954;
    CrossrefPubMedGoogle Scholar
  • (15) Sterling K. The Turnover Rate of Serum Albumin in Man as Measured by I131-Tagged Albumin. J. clin. Invest. 30: 1228 1951;
    CrossrefPubMedGoogle Scholar
  • (16) Waaler B. A. Contact Activation in the Intrinsic Blood Clotting System. Scand. J. clin. Lab. Invest. 11 Suppl. 37 1959;
    CrossrefPubMedGoogle Scholar